Direxion Daily S&P Biotech Bear 3X ETF
LABD
12 hedge funds and large institutions have $23.7M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
751% more call options, than puts
Call options by funds: $34.7M | Put options by funds: $4.07M
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
16% more capital invested
Capital invested by funds: $20.5M → $23.7M (+$3.23M)
9% more funds holding
Funds holding: 11 → 12 (+1)
0.11% more ownership
Funds ownership: 0.01% → 0.13% (+0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.42M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.44M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.48M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$358K |
| 5 |
HF
HRT Financial
New York
|
+$243K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$492K |
| 2 |
Jane Street
New York
|
-$243K |
| 3 |
Citigroup
New York
|
-$78.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $11.1M | +$6.42M | +1,058 | +97% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $3.54M | +$2.44M | +403 | +143% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $2.67M | +$1.48M | +244 | +90% |
|
4
SG Americas Securities
New York
| $2.59M | – | – | – |
|
|
VF
5
Virtu Financial
New York
| $1.58M | +$66.7K | +11 | +4% |
|
|
6
Citadel Advisors
Miami,
Florida
| $671K | +$358K | +59 | +83% |
|
|
7
Citigroup
New York
| $648K | -$78.8K | -13 | -9% |
|
|
8
Jane Street
New York
| $282K | -$243K | -40 | -43% |
|
|
TSS
9
Two Sigma Securities
New York
| $210K | +$243K | +40 | New |
|
|
HF
10
HRT Financial
New York
| $209K | +$243K | +40 | New |
|
11
Royal Bank of Canada
Toronto,
Ontario, Canada
| $170K | +$200K | +33 | New |
|
|
CG
12
Cutler Group
San Francisco,
California
| $7K | – | – | – |
|
|
CS
13
Credit Suisse
Zurich,
Switzerland
| – | -$492K | -67 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$15K | -2 | Closed |
|
LABD Hedge Fund Activity: Q2 2018 in Review
12 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q2 2018, worth a combined $23.7M — up 16% from $20.5M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LABD positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $6.42M. The largest seller was Credit Suisse, exiting entirely with an estimated $492K sold.
- 12 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q2 2018, up from 11 in Q1 2018.
- Funds reported $23.7M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q2 2018, up 16% quarter-over-quarter.
- 3 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q2 2018 and 2 closed out, a net change of +1 holder.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q2 2018 was Morgan Stanley, an estimated $6.42M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q2 2018 was Credit Suisse, an estimated $492K sold.
Based on aggregated 13F filings for Q2 2018.